Clinical trial
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
NCT01508702 is registered in ClinicalTrials.gov with Ardea Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
- Lead sponsor
- Ardea Biosciences, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- November 30, 2013
- Enrollment
- 214 (actual)
- Sites
- 106
Conditions
As the registry lists them; a condition with its own page is linked.